Peter S. Kim
Tumor immunology


AB, Chemistry, Cornell University

PhD, Biochemistry, Stanford University

My laboratory aims to create vaccines that are needed for important infectious diseases and to devise new strategies to enable vaccine creation. Our vaccine targets include HIV-1, pandemic influenza, Ebola and SARS-CoV-2. Our vaccine research is primarily focused on antibody-mediated immune responses, so our work involves investigation of antigen-antibody interactions and the interrogation of B cell populations.

We are also interested in establishing approaches to enable small-molecule drug discovery toward targets that have proven refractory (i.e., “undruggable” targets). One of the targets that we study is the HIV-1 gp41 hydrophobic pocket involved in viral membrane fusion during HIV infection. Another is the immune checkpoint protein PD-1. Anti-PD-1 antibodies have shown dramatic effects in some cancer patients. These drugs work by enhancing the endogenous anti-tumor activity of T cells. We want to enable discovery of small molecules that target immune-checkpoint proteins. Such drugs could offer safety advantages due to their far shorter half-lives as compared to antibodies, and possibly potentially greater efficacy owing to their greater penetration and distribution within the tumor microenvironment.


Ludwig Center at Stanford
Lokey Stem Cell Research Building
265 Campus Dr., 3rd Floor
Stanford, California, U.S. 94305-5323

T 650 234 0675


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?